A grand cardiovascular expert seminar was held in Tel Aviv, Israel from December 4th to 6th, 2016, and ICICO (Israel China Cardiovascular Innovation Cooperation Organization) was officially established. The conference was chaired by Rafi Beyar, Chief Scientist of the Israeli Ministry of Economy, Academician Ge Junbo, Professor Chaim Lotan, Founder and President of ICI, and Head of the Cardiovascular Department at Hadassah Medical Center in Israel, among others, and a cooperation agreement was officially signed. Academician Ge Junbo is currently an academician of the CAS Member, chairman of the Cardiology Branch of the Chinese Medical Association, vice president designate of the Cardiology Branch of the Chinese Medical Association, chairman of the Asia Pacific Interventional Cardiology Society, and international consultant of the American Heart Association. This is the first cooperation between the cardiovascular medical community of China and Israel in the form of a joint organization. More than 1600 participants from 44 countries discussed the future of medical development and the medical process of aging society in the fields of coronary intervention, vascular intervention, stroke prevention and intervention.
According to the cooperation agreement, both parties will provide exclusive support to each other in promoting cardiovascular academic exchanges, industry development, and capital cooperation. The newly established ICICO will be committed to promoting a series of China Israel cardiovascular medicine collaborations, including youth exchanges, through academic cooperation, conference organization, and corporate investment. In addition, the new organization may have the opportunity to establish an accelerator in Israel to increase innovation participation in the Chinese Israeli cardiovascular community. The era of 'Made in China' has now been replaced by China's demand for high-tech innovation, and Israelis have also realized that real development is in Asia, where the real big market is, "Mr. Lotan said.
As the first president of the China Innovation Association, Academician Ge Junbo's speech at this conference was particularly noteworthy. Academician Ge highly praised Guangdong Pulse Medical Technology Co., Ltd. as a well-known domestic medical enterprise for its outstanding contributions in innovation, research and development, production, and introduction in the field of cardiovascular diseases during the meeting. At the academic symposium, Chen Wei, the director of the Department of Cardiology at Shanghai Tenth People's Hospital, represented the domestic cardiovascular innovation team and introduced the technology and device of left atrial appendage occlusion to cardiology experts around the world from a clinical medical perspective. The team led by Xu Yawei, Director of the Heart Center of Shanghai Tenth People's Hospital, has been committed to innovative research in multiple products in the field of heart disease for many years. Especially in the clinical research of left atrial appendage occlusion devices, they have introduced a large number of high-level personnel for scientific research and invested a lot of research funds. They have successfully completed more than 200 clinical implantation surgeries of percutaneous left atrial appendage occlusion devices and have become the hospital with the largest number of left atrial appendage occlusion surgeries in the Asia Pacific region. In Director Chen Wei's case report, there is also a comparison of the advantages and disadvantages of several major left atrial appendage implant products that have entered clinical applications internationally and clinical trials domestically. In particular, the new generation of left atrial appendage occluder LeftearTM, jointly developed by the Heart Center of Shanghai Tenth People's Hospital and Guangdong Pulse Medical Technology Co., Ltd., was introduced. The LeftearTM left atrial appendage occlusion system has a more complete left atrial appendage occlusion compared to Watchman's products and St. Jude Medical's ACP products, without affecting surrounding tissues. This product has completed thirteen animal experiments and has entered the stage of product type inspection. Afterwards, clinical trials will be led by Academician Ge Junbo at 8-10 centers in China. At the same time, Academician Ge inspires us to develop more innovative cardiovascular products under the leadership of Director Xu Yawei of the Heart Center of Shanghai Tenth People's Hospital, in order to benefit humanity.
In the process of innovation, whether in Israel or Silicon Valley in the United States, the chain of innovation industrialization is very clear: clinical doctors will start from clinical needs and transform the problems encountered in clinical work into clinical ideas; Engineers and doctors collaborate to translate clinical ideas into concrete products, which are then driven by investors and enterprises to be implemented. Therefore, the innovative power of clinical doctors combined with clinical needs in the clinical field has enormous value. Abroad, investors see the value of clinical doctors in the field of innovation. China has the largest sample size, the largest group of doctors, and the most complex diversity of medical records. It is believed that in this land, it is very possible to generate medical technology and device innovation that will have an impact on the world. ICI has been held for 21 years and has now become one of the most important international conferences in the field of cardiovascular medicine. Since the participation of Chinese participants five years ago, cooperation in the field of traditional Chinese medicine and cardiovascular medicine has gradually increased. In 2015 alone, China's investment in Israeli cardiovascular startups reached one billion US dollars.
At the exhibition, Guangdong Pulse Medical Technology Co., Ltd. held talks with several domestic and foreign companies dedicated to the medical and health industry and reached preliminary cooperation intentions. In the future, more advanced equipment and products will be introduced. Including apex drainage device, whole-body DSPECT high-definition scan, left ventricular assist device, adjustable curved microcatheter, etc. Guangdong Pulse Medical Technology Co., Ltd. has completed the construction of its factory in the High tech Zone and plans to officially start production in February 2017. At the same time, in order to improve the company's scientific research capability, we will introduce academician Chen Yihan of the Chinese Academy of Sciences and his team to jointly develop cardiac intervention products with Guangdong Pulse Medical Technology Co., Ltd. Chen Yihan, cardiologist, academician of the CAS Member. Professor, chief physician, and doctoral supervisor at Tongji University. Member of the 12th National Committee of the Chinese People's Political Consultative Conference and Vice Chairman of the Shanghai Municipal Committee of the Jiusan Society. Recipient of the National Outstanding Youth Science Fund, Changjiang Scholar Distinguished Professor of the Ministry of Education, Chief Scientist of the National 973 Program, and Head of the National Innovation Research Group. Professor Chen Yihan has made outstanding achievements in the field of cardiovascular disease research. Revealing the genetic and electrophysiological mechanisms of various arrhythmias; Propose that the myocardial cell logistics system can widely regulate cardiac electro-mechanical function; Discovery of the molecular valve effect of mitochondrial outer membrane transposition enzyme complex subunits in the occurrence of chronic heart failure in cardiomyocytes; Identify a novel mechanism of adrenergic receptor regulation in cardiac oxygen metabolism. The landmark achievements have been published in international authoritative journals such as Science, Nature Communications, Cell Research, J Clin Invest, and Circulation Research. Professor Chen Yihan's scientific discoveries have been written into dozens of foreign textbooks and monographs; The international diagnostic and treatment guidelines have also cited their work multiple times. He has won the second prize of the the State Natural Science Award, the first prize of the Natural Science Award of the Ministry of Education, the first prize of the Shanghai Natural Science Award, the Peony Award of Shanghai Natural Science and the Chinese Physician Award. Under the guidance of Academician Chen Yihan, we believe that the product research and development capabilities of Guangdong Pulse Medical Technology Co., Ltd. will reach an international advanced level.